In patient #5, splenomegaly and symptoms improved, but thrombocytosis and JAK2 V617F VAF remained unaffected on 30 mg total daily dose of ruxolitinib, which was therefore increased to 40 mg daily. The gene discussed is JAK2; the disease is Splenomegaly.